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Heavy ions, such as carbon and oxygen ions, are classified as high-LET radiations, and produce a
characteristic dose-depth distribution different from that of low-LET radiations such as g-rays, x-
rays and electrons. Heavy ions lose less energy at the entrance to an irradiated biological system
up to some depth than the low-LET radiations, while they deposit a large amount of dose within a
very narrow range at a certain depth, producing the characteristic sharp peak called the Bragg
peak. Therefore, by controlling the Bragg peak, it becomes possible to irradiate only the tumor
region in a pin-point manner, while avoiding irradiation of the normal tissue, thus making heavy-
ion therapy ideal for deep-seated tumor treatment. Clinical results on more than 2400 patients
are very encouraging. However, very little is known about what is going on in terms of physics and
chemistry inside the Bragg peak. In this paper the current status of our understanding of heavy-ion
interactions and remaining problems of physics and chemistry for the heavy-ion treatment are ex-
plored, particularly in the Bragg peak region. Specially, the survey of the basic physical quantity,
the mean energy required to form an ion pair (W value) for heavy ions of interest for radiotherapy
is presented. Finally, the current clinical status of heavy-ion therapy is presented.
Key words: Heavy ions, radiation therapy, W value, Bragg peak, oxygen enhancement ratio
(OER), relative biological effectiveness (RBE), radicals, ion-bio-molecule interaction,
deep-seated tumor
Introduction
Clinical applications and testing of new medical irradiation
facilities using heavy ions such as carbon-ions were started
in Japan and Germany in 1994. A successful control rate of
various tumors in over 2400 patients with otherwise mostly
untreatable cases was achieved. The basic principle un-
derlying radiation cancer therapy is to induce damage in
cancerous cells (mostly by ionizations) so that they cannot
grow and multiply, while minimizing damage to the surro-
unding healthy tissue. Following this principle, heavy ions
(high-linear energy transfer (LET) radiations) have several
advantages over conventional radiation therapies based on
g-rays, x-rays and electrons (low-LET radiations) in clinical
applications particularly for tumors in deep-seated hypoxic
conditions. Photons lose their energy and deliver the dose
before they reach the (deep-seated) tumor, and travel be-
yond the location of tumor, thus damaging healthy cells and
causing undesirable side-effects. Low-LET particle beams
(protons, helium ions) improve the physical selectivity of
the irradiation; however, little benefit is obtained with re-
spect to radiobiological effects (relative biological effective-
ness ranges between 1.1 and 1.3).1–3 High-LET radiations
(fast neutrons, heavy ions) produce different biological ef-
fects. What makes the heavy-ion therapy so unique is based
on a few physical aspects of their interaction with irradiated
matter in comparison to those of low-LET radiations: (i)
heavy ions deposit their energy at a certain well-defined
depth of tissue (the Bragg peak) which depends on the
energy of the ion, and beyond that depth the ions are com-
pletely stopped, while between the entrance into a human
body and the Bragg peak the delivered dose is almost con-
stant but lower than at the Bragg peak position, (ii) heavy
ions are more efficient in producing biological damage for
the same delivered dose, and thus they have been assigned
higher relative biological effectiveness (RBE), in comparison
to other radiations such as g-rays, and (iii) the reduction in
OER (Oxygen Enhancement Ratio) is obtained. The lower
the OER, the more effective (i. e. less damaging to normal
tissue) the treatment with a given radiation. Hence, by con-
trolling the Bragg-peak position, it should be possible to
establish an efficient and a close-to-ideal treatment plan in-
volving only tumor region in a much pin-point fashion, whi-
le not affecting normal tissues in front of or beyond the
tumor. By targeting tumors more accurately and delivering
larger radiation doses, the treatment can eventually be ac-
celerated. There is also evidence for the reduction of diffe-
rences in radio-sensitivity to high-LET radiations related to
cell cycle phase, to cell line, or a reduced importance of
repair phenomena.4 Under these conditions, all cell popu-
lations, in all situations when exposed to high-LET, as com-
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pared to low-LET radiations, tend to respond in a similar
way.
For the more effective use of radiations, it is essential to un-
derstand radiation physics and chemistry in the Bragg peak
region, although systematic understanding of what is going
on along the entire path of radiation (track) would be im-
portant, as well as beyond the Bragg peak.5 In this article,
we will review radiation physics and some chemistry when
radiations (electrons and heavy-ions) with the initial energy
of up to a few MeV are acting on biological systems, particu-
larly in the Bragg peak region. Finally, we discuss actual ap-
plications and clinical test cases.
Radiation physics and chemistry
Heavy charged particles slow down, i. e. lose their initial
energy, as they travel through a material as a result of
electromagnetic interactions between the positive charge
of the ion and the negative charge of the orbital electrons of
the material. The products of these interactions are either
excited atoms or ion pairs, i. e. pairs consisting of a free
electron and the corresponding positive ion. For photon
and electron impacts, ionization and excitation processes
also take place and many secondary electrons are released.
In both cases these secondary free electrons are used as a
basis for the detection of ionizing radiation by a detector.
The initial energy of photons, electrons and protons is usu-
ally expressed in keV or MeV, while that of heavy ions is ex-
pressed as MeV/amu, where amu is the “atomic mass unit”.
Dose, LET, and OER
Two different materials, exposed to the same radiation
field, will in general absorb different amounts of energy.
The energy absorbed per unit mass is called the absorbed
dose, and the unit is 1 Gy = 1 J kg–1. The absorbed dose is a
meaningful measure of chemical and/or physical effects
created in an absorbing material by a given amount of radi-
ation energy. Therefore, measurement (or the knowledge)
of the energy absorbed per unit mass is of fundamental inte-
rest in the studies of physical and chemical effects of radiati-
on in matter.
However, when the effects of radiation on living organisms
are studied, the absorption of equal amounts of energy per
unit mass (the same absorbed dose) under different irradia-
tion conditions may cause different biological effects. The
magnitude and the severity of the biological effect can differ
by as much as an order of magnitude depending on the lo-
cal rate of energy deposition (through excitation and ioniza-
tion processes) along the particle track. This quantity is
known as LET – linear energy transfer, i. e. the amount of
energy (dE) dissipated by the incident charged particle per
unit distance (dl) as it traverses through the matter, LET =
dE/dl. LET is expressed usually in keV/m. Regarding their
LET, ionizing radiations can be generally divided into low-
LET and high-LET radiations, with the demarcation value of
10 – 20 keV/m.6,7 High-LET radiations, such as heavy ions
(LET = 100 – 200 keV/m6), tend to result in greater biologi-
cal damage than low-LET radiations (x-rays, electrons) even
though the total energy deposited per unit mass (dose) may
be the same.
Biological effect of ionizing radiation can be influenced by
the presence of molecular oxygen within the cell – the lar-
ger the cell oxygenation, the larger the biological effect of
radiation.6 The oxygen enhancement ratio (OER) is thus de-
fined as the ratio of the dose without oxygen to that in the
presence of oxygen that produces the same biological effect
(Fig. 1).6,8 The OER for low-LET radiation is about 3, and it
decreases as the LET increases, approaching OER = 1 at
about LET = 150 keV/m (Fig. 2). It has been a widely ac-
cepted notion in radiation-physics and radiation-chemistry
communities that two modes of radiation action are pos-
sible: a direct one and an indirect one.6 The direct effect is
apparently the consequence of a direct hit of DNA mo-
lecule by radiation causing single- and double-strand bre-
aks, and it is the dominant process in the interaction of
high-LET particles with the biological material.6 The indirect
effect is the consequence of radiation hitting water and ot-
her molecules surrounding DNA producing radicals and
ions, which, in turn, attack DNA, thus causing its damage.
Hence, the presence of water and other molecules is es-
sential for the indirect effect. Generally, the direct effect
amounts to about 30 % of the total radiation effect induced
by low-LET radiation (x-rays), while the indirect effect is
about 70 %, and hence, the indirect effect is considered to
dominate the total radiation effect,4,6 and it will be dis-
cussed in detail later. Blood circulation in the central area of
a large deep-seated malignant formation is poor, and hence
sufficient oxygen is not brought into the center of the malig-
nant formation resulting in hypoxia, while the normal tis-
sues are – in general – well oxygenated. As Fig. 1 shows, the
radiation effect is higher under oxic conditions, and beca-
use of this, radiation treatment is considered relatively less
effective. However, the oxygen enhancement ratio is lower
for high-LET radiations than for low-LET radiations (Fig. 2),7
and the lower the OER , the more effective (i.e. less dama-
ging to normal tissue) the treatment with a given radiation.
This certainly means that high-LET radiation is more effecti-
ve regardless of the presence of oxygen.
The Bragg peak and RBE
The characteristic of heavy ions when interacting with the
material is that they are more efficient at ionizing atoms
along their path as they move slower. This means that the
highest radiation dose is delivered at the point in the body
at which they stop while the dose elsewhere is much lower.
The plot of absorbed dose as a function of depth of the ab-
sorbing medium/tissue (the Bragg curve or dose-depth dis-
tribution) has then a characteristic, very pronounced peak
at a certain depth – the so-called Bragg peak (Fig. 3). The
Bragg peak can be moved to shallower or deeper depths by
changing the energy of the ion beam or by interposing ma-
terial upstream to alter the beam energy,9 thus allowing one
to control the Bragg peak position. Moreover, by combining
several ion beams of slightly different energies, an almost
uniform dose distribution over a certain depth of tissue
(over the entire tumor) can be obtained, and such a distri-
bution is called the spread-out Bragg peak (SOBP).10,11 This
makes the clinical application more effective. In contrast,
the dose-depth distribution for photons/x-rays shows a ma-
ximum close to the surface (skin), which is a consequence
of the build-up of secondary electrons, followed by the
nearly exponential decrease (Fig. 3), and the ratio of the
dose delivered to the tumor relative to the dose delivered to
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the surrounding tissue is much lower for photons than for
heavy ions.10
Therefore, heavy-ion beams are excellent tools for the
treatment of deep-seated tumors, because of the enhanced
energy deposition at the end of the (heavy) particle range
and the corresponding decrease of cell survival. Both model
calculations and measurements show a considerable de-
crease in survival rate of cells irradiated by carbon ions at
the depth corresponding to the position of the Bragg
peak.12 Similar Bragg curves with a maximum delivered
dose at a certain energy-dependent depth are obtained also
for protons (Fig. 3). By combining protons of different ener-
gy the SOBP can be produced, and proton therapy can be
successfully applied for certain types, positions and sizes of
tumor.7
Different kinds of radiation have different levels of effecti-
veness when it comes to ionizing molecules in living tissue.
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F i g. 1 – Dependence of the biological effect of radiation (i.e. fraction of cells surviving irradiation by a given dose, cell surviving curves)
on the absorbed dose in oxic and hypoxic conditions for low-LET (left) and high-LET radiations (right). Oxygen Enhancement Ratio (OER) is
defined as the ratio of doses resulting in the same biological effect under hypoxic and oxic conditions, as illustrated by dotted lines. Schema-
tic presentation prepared after ref.6,8
S l i k a 1 – Ovisnost biološkog uèinka zraèenja (t. j. udio stanica preÞivjelih ozraèenost danom dozom) o apsorbiranoj dozi u uvjetima s
prisustvom kisika (oxic) i bez prisustva kisika (hypoxic) za zraèenje niskog LET (lijevo) i visokog LET (desno). Omjer pojaèanja zbog prisustva
kisika (OER) definiran je kao omjer doza koje daju isti biološki uèinak u uvjetima bez kisika i s kisikom, što je ilustrirano istoèkanim linijama.
Shematski prikaz prema ref.6,8
F i g. 3 – Dose-depth distributions, i.e. dose delivered throughout
the depth of the tissue, for x-rays, protons, carbon ions of two ener-
gies, and the spread-out Bragg peak (SOBP). The distinctive Bragg
peaks in the curves for protons and C ions are observed. Dose-
depth distribution peak is observed at deeper depths for higher ion
energy. The SOBP is obtained by combining ions of different ener-
gies. Prepared after ref.10,11
S l i k a 3 – Raspodjela doze po dubini prodiranja zraèenja u tkivo
za x-zrake, protone, ugljikove ione dviju razlièitih energija, te proši-
reni Braggov vrh (SOBP). Krivulja raspodjele doze za protone i
ugljikove ione pokazuje izraziti maksimum, Braggov vrh, koji se
opaÞa na veæim dubinama za veæe ionske energije. Prošireni Brag-
gov vrh dobije se kombinacijom iona razlièitih energija. Pripremlje-
no prema ref.10,11
F i g. 2 – Dependence of OER and RBE on LET of radiation.
Schematic presentation prepared after ref.6,8
S l i k a 2 – Ovisnost omjera pojaèanja u prisustvu kisika (OER) i
relativne biološke uèinkovitosti (RBE) o linearnom prijenosu energi-
je (LET) zraèenja. Shematski prikaz prema ref.6,8
The ratio of the absorbed dose of a reference radiation (nor-
mally x-rays or -rays of 200 keV) to the absorbed dose of a
test radiation required to produce the same level of biologi-
cal effects, all other conditions being equal, is called relative
biological effectiveness (RBE).6 (It should be pointed out
that different RBE values can be assigned to different biolo-
gical effects, such as single or double strand breaks of DNA,
non-reparable DNA breaks, cell inactivation, etc, even for
the same type of radiation.6,13 In this paper we restrict the
discussion to the RBE for cell inactivation/killing.) The RBE is
also regarded as a measure of the benefit versus risk of radi-
otherapy – the higher the RBE, the lower the dose needed
for the same biological effect. Namely, radiotherapy aims to
irradiate tumor with sufficient dose to achieve local control
while minimizing complication in normal tissue. However,
probabilities of both these effects increase with increasing
dose6,10,14 (Fig. 4). The larger the distance between the tu-
mor control probability (TCP) and the normal tissue compli-
cation (NTCP) curves, the easier it is to achieve the thera-
peutic goal, and the less likely the complications.6 There is
an optimum region of doses where TCP0.5 and NTCP
0.5 (between dotted lines in Fig. 4) called a “therapeutic
window”, where the probability of tumor control without
normal tissue complications (shaded area in Fig. 4) has its
maximum (Fig. 4). Therefore, the lower the dose for the
same radiation effect, the less the complication on healthy
tissue.
RBE depends on several variables, such as the particle type
and energy, the absorbed dose and the biological system.
Usually the RBE is correlated to the value of LET (Fig. 2). For
low LET values, RBE is common for all particles and is close
to 1. For protons the maximal RBE of about 1.3 is found at
25 keV/m.13 The RBE increases with LET reaching a
maximum at a certain LET value depending on the ion. The
position of the maximum RBE shifts to higher LET values for
heavier ions:15 maximum RBE for helium ions is observed at
100 keV/m, and at 200–300 keV/m for carbon ions.13
The value of the RBE provides a quantitative index of the ef-
fectiveness per unit of absorbed dose of any radiation. For
example, the RBE of 2.6 – 2.9 for neon ions16 was determi-
ned at the Bragg peak, while for carbon ions of 13 keV/m
(LET) and 77 keV/m the RBE of 1.0 – 1.3 and 2.0 – 3.0, re-
spectively, were reported.17 RBE varies also with the depth
in the irradiated medium – RBE for C ions having energy
194 MeV/amu is calculated to be 1.7 at the entrance to the
tissue, maximum value 3.6 at the depth corresponds to the
Bragg peak, and is 1 beyond the peak.18 Clinical experience
and studies on human cells resulted in RBE of 3.0 for carbon
ions having energy 290 MeV/amu (LET is about 80 keV/m)
in the region of SOBP.19
Therefore, the Bragg peak region is the most effective regi-
on for treatment by heavy ions, and hence detailed physics
and chemistry occurring in the Bragg peak is essential for
better planning and design of the treatment. In the existing
facilities, heavy ions with about 300 MeV/amu-energy are
used for irradiation, and they first lose their kinetic energy
and momentum through elastic scattering with constituent
atoms and molecules in a system. In the energy region of a
few hundred keV/amu, the ionization and electronic exci-
tation rapidly become dominant processes thus causing loss
of large amounts of energy. This is the region where the
Bragg peak begins, and these collision processes are in fact
essential for it. For example, a beam of 290 MeV/amu car-
bon ions produces 5 times more ionizations (i.e. electron-
ion pairs) at the maximum of the Bragg peak than at the en-
trance into a tissue.20 Near the tail of the Bragg peak where
the incident-ion energy is somewhere in the keV to high-eV
region, all other collision processes are expected to play
crucial roles, of which charge transfer, rotational and vibra-
tional excitations, electron attachment (secondary elec-
trons), and reactive scattering are important. Molecular ions
produced through ionization and charge transfer, and those
species produced by electronic excitations are often un-
stable undergoing fragmentation within a lifetime of less
than 10–12 s. This fragmentation produces radicals and ions
with appreciable kinetic energy sufficient to travel further
out from the track of the incident ions. These products un-
dergo a series of reactions with other surrounding mo-
lecules further producing different types of new chemical
species. They all can eventually react with biological mo-
lecules causing biological damage. Therefore, the series of
radiolysis events, i.e. initial ionization and excitation, pro-
duction of fragmented species, secondary radical reactions,
as well as the behavior of secondary electrons, as a whole,
are the origin of the Bragg peak and hence of the radiation
effect.
As discussed above, heavy-ions possess several advantages
over low-LET radiations with respect to the OER and RBE,
but the full physical and chemical picture is yet incomplete.
It is usually thought that high-LET radiation is more efficient
in producing direct hits to DNAs, while the effects of low-
LET radiations are dominantly produced by radical reacti-
ons.4,6 As it is well known, the dominant material constitu-
ting biological systems, including the human body, is the
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F i g. 4 – Dose-dependence of the tumor control probability
(TCP) and the normal tissue complication probability (NTCP). The-
rapeutic window is defined as the dose region where TCP > 0.5
and NTCP < 0.5 (range between dotted lines). The probability of
tumor control without normal tissue complication (shaded area)
has a maximum in the therapeutic window. Prepared after ref.6,14
S l i k a 4 – Ovisnost vjerojatnosti kontrole tumora (TCP) i vjero-
jatnosti komplikacija zdravog tkiva (NTCP) o primljenoj dozi tije-
kom radioterapije. Podruèje doza za koje vrijedi TCP > 0,5 i NTCP
< 0,5 (izmeðu crtkanih linija) naziva se “terapijski prozor”. Vjero-
jatnost kontrole tumora bez komplikacija zdravog tkiva (osjenèano
podruèje) najviša je upravo u terapijskom prozoru. Pripremljeno
prema ref.6,14
water molecule – more than 70 % of the human body mass
is water. Hence, upon irradiation, the majority of radiation
energy is considered to interact with water molecules pro-
ducing radicals OH, H, O2
, etc, and these radicals inte-
ract rapidly with nearby DNA causing the indirect effect.
As a general example of an indirect radical – DNA reaction,
we discuss here the following process involving water mo-
lecules. Direct dissociation of the electronically excited wa-
ter molecule (H2O*H
 + OH) results in production of
H and OH radicals, with relatively large kinetic energies
allowing them to travel further. These fragments have very
fast reaction rates and thus they almost immediately (within
10–12 s) react with the atoms and molecules they encounter
while traveling. Dissociation through ionization of water
molecule (H2O  H2O
 + e – ) results in unstable H2O

ions that either undergo fragmentation producing H ions
and OH radicals, or react with other water molecule (H2O

+ H2OH3O
 + OH) producing H3O
 ions and OH
radicals. On the other hand, electrons produced through
ionization lose their kinetic energy in a series of collisions
with various molecules, and within about 10–12 s become
thermalized. Since water molecules are strong polar mo-
lecules, they orientate toward a thermalized electron and
form energetically a stable state called a solvated electron,
eaq
– . The solvated electron is a transient species found in all
systems where the charge is transferred through a medi-
um.21 It is highly reactive22 and plays a key role in radiation
chemistry in various aspects, e. g. in cancer radiotherapy or
neutralization of toxic wastes.21 In reactions of the solvated
electron with water molecules (eaq
– + H2OOH
– + H)
and H ions (eaq
– + H H) H radicals are produced.
Therefore, through ionization and electronic excitation of
water molecules by incident radiation, a large amount of
solvated electrons and various types of radicals (most im-
portant are OH and H) and ions are produced. The distri-
bution of radical species depends on the type of radiation –
for high-LET radiation such a distribution is very dense, whi-
le for low-LET radiation it is sparse. When the density of ra-
dicals is high enough, they recombine and disappear, e. g.
OH + OH H2O2, H
 + H H2, H
 + OH H2O).
Finally, although heavy ions deposit more energy per unit
length, the yields of free radicals per 100 eV absorbed ener-
gy are up to one or two orders of magnitude smaller for hi-
gh-LET radiation than for x-rays.23 Therefore, for high-LET
radiations, the effects of radical reactions are considered to
be of a secondary importance, while for low-LET radiations,
they are the primary precursors of radiation effects. Mo-
deling of DNA damage by electrons of various energies
shows that between about 50 % and 70 % of DNA damage
is caused by the indirect effect, mostly by interactions with
the OH radicals.24 However, the investigations aimed at
elucidation of these phenomena are scarce when high-LET
radiation is concerned, and the reason why it is so may be
related to the paucity of well characterized heavy ion so-
urces. Also a higher sensitivity of measuring devices is requ-
ired, as well as their good spatial and temporal resolution.
Consequently, further investigations of both direct and indi-
rect effects of heavy ions on DNA are needed inside the
Bragg peak.
The region beyond the Bragg peak consists often of healthy
tissue, and this fact enhances the concern of a potential da-
mage on a molecular scale caused by heavy ions after they
have lost most of their energy or by low-energy (< 200
eV/amu) secondary ions. Until very recently, it has been wi-
dely believed that low-energy ions below a hundred or a
few tens of eV/amu may have nearly null radiation effect
since they do not possess sufficient energy to induce ioniza-
tion, excitation and charge transfer upon interactions. A re-
cent study,5 however, indicates that beyond the Bragg peak
more harm to the healthy tissue is caused by low-energy se-
condary particles than by heavy ions themselves. Hence,
the effects induced by low-energy ions in the region be-
yond the Bragg peak should also be thoroughly investi-
gated.
Ionization and W value
In radiation therapy, the clinicians must design a method of
irradiation so that a desired dose may be delivered to a
specific region of treatment, with a minimum dose delive-
red elsewhere. To optimize dose delivery to a tumor, one
must know the energy deposition in a tissue or tissue-like
material, and this is the central problem of accurate do-
simetry. As mentioned earlier, the universal final products
of an interaction of any ionizing radiation are free electrons,
which are detected by various types of radiation detectors.
The uncertainty of the measured energy deposited in a tis-
sue depends on the quality of basic physical data, such as
stopping powers and total ionization yields produced by in-
cident particles of various charge and various energies.
The penetration depth (or a range) of a charged particle in
matter is characterized by the mean energy loss per unit
path length, or the stopping power. Stopping powers for
electrons and positrons were critically surveyed in the ICRU
Report 37,25 while those for protons and alpha particles
were presented in the ICRU Report 49.26 Recent ICRU Re-
port 73 presents a critical survey of the measurements and
calculations of stopping powers for ions from lithium to ar-
gon (Z = 3 – 18) of energies from 1 keV/amu upward in
condensed and gaseous matter.27
The other basic quantity for dosimetry is the ionization
yield, i.e. the number of electrons produced by radiation in
matter. The related quantity “average energy to produce an
ion pair” (W value) is used more often. The W value is defi-
ned as the mean energy (expressed in eV) spent by the inci-
dent particle of energy E for the formation of a pair of an
electron and a positive ion after complete dissipation of the
initial energy, W = E/N, where N is the total number of pro-
duced electron-ion pairs. As it was the case for the stopping
power, W value depends on the type and energy of radiati-
on and on the irradiated material. The W value is defined
after complete dissipation of the initial energy of the inci-
dent particle to matter. However, for high-energy particles
in thin media, it is necessary to consider the differential w
value, defined as w = dE/dN, where dE is the mean energy
lost by a charged particle of energy E in traversing an ab-
sorber of thickness dx, and dN is the mean number of ion
pairs produced when dE is completely dissipated in the gas.
For sufficiently high incident energy W = const, and w = W
is a good approximation.
Accurate knowledge of the characteristics and values of W
and/or w is required for conversion of the charge collected
in the ionization chamber to deposited energy, and un-
certainties in W values directly influence the overall uncer-
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tainties in measured dose. For radiotherapy it is desirable to
determine doses in tissue with overall absolute uncertainty
of 5 % or better,28–30 and it implies that the separate contri-
butors to dose calculation (W or w values, stopping powers,
etc.) should be known with absolute uncertainties of 2–3 %.
However, available data on W or w are often fragmented,
deficient, dispersed, and missing systematic. Since stopping
powers for ions have been recently surveyed,27 the current
knowledge on W and w values for heavy ions will be dis-
cussed here in more detail.
The ICRU Report 3131 and Chapter 8 in the IAEA TECDOC
79928 provide a basis for assessing the present knowledge of
W values for different charged particles in various gases. It
should be pointed out that all W values are measured and
reported for gases (N2, CH4, C3H8, CO2, Ar, air) as irradiated
material, although in radiation therapy one actually deals
with the tissue as a complex material. Dosimetric mea-
surements, including those of W, are often performed on
gaseous tissue-equivalent (TE) mixtures. Most common TE
gas mixtures, simulating the composition of tissue, are met-
hane-based TE gas (64.4 % CH4, 32.4 % CO2, 3.2 % N2, by
volume), propane-based TE gas (55 % C3H8, 39.6 % CO2,
5.4 % N2), and butane-based TE gas (51.4 % C4H10, 42.3 %
CO2, 6.3 % N2).32 The TE gases are essential in mea-
surements of radiation energy deposition in small spheres
simulating human cells. The dose distribution curves on the
cell-size level (0.1 – 10 m sphere diameter) are indispens-
able in human radiotherapy, especially when neutrons and
heavy particles are applied.18,33,34 When complex substan-
ces are involved, an important practical and theoretical
problem arises – the analysis of the validity of the additivity
rule or how to derive W values for complex substances from
the W values for their constituents. Experimental W values
for heavy ions (C, O, N) and also other incident particles in
TE gas mixtures were compared with the W values calcu-
lated from W values for pure components by applying vari-
ous mixing models and the model giving the best agree-
ment was identified.32,35
Dosimetry in heavy-ion therapy is performed by ionization
chambers filled with air, and the measured values are then
converted to doses in water or in tissue. Detailed descripti-
on of the calculation method is beyond the scope of this re-
view. The procedure of absorbed dose determination
based on ionization chamber dosimetry is recommended
by IAEA,29 and this is currently the only international gui-
deline for clinical dosimetry of ion beams. Additional deta-
ils may be found elsewhere.30,36,37
High-energy heavy ions used in radiotherapy have a consi-
derably different range of charge, mass, and velocity than
the electrons and alpha-particles, for which there are exten-
sive measurements of W. The heavy ions considered for use
in radiotherapy include He, C, Ne, Si and Ar. The appropri-
ate energies to obtain a sufficient beam penetration are
typically 250 MeV/amu for He, 200 – 400 MeV/amu for C,
620 MeV/amu (Ne), 800 MeV/amu (Si), and 860 MeV/amu
(Ar). The existing W or w data are fragmentary and most of
them are measured for relatively low energies below 1 MeV
where major variations in energy dependence are obser-
ved.28,31 There is a lack of experimental data in the energy
range above 1 MeV/amu, which is of interest for radio-
therapy. Recently, two groups from the heavy-ion therapy
centers (GSI and HIMAC) started a new series of w value
measurements for high-energy carbon and some other
ions.38,39 The available w values for ions of interest at higher
energies38–45 are shown in Table 1. For comparison, some W
values for high-energy electrons28,31,35 (> 10 keV), high-e-
nergy protons2,31,35,40–42 (> 100 keV) and 5–MeV alpha-par-
ticles31,39 are also presented in Table 1.
T a b l e 1 – W values for electrons, protons and -particles,
and w values for heavy ions
T a b l i c a 1 – W za elektrone, protone i -èestice, te w za teške
ione
Particle
Èestica
Energy
Energija
Gas
Plin
W or w (eV)
W ili w (eV) ref.
electrons >10 keV methane 27.3 ± 0.3 31
methane-TE 29.4* 28
propane 24.0 ± 0.5
25.9 ± 0.7
31
28
propane-TE 27.0 ± 0.3 35
air 33.97 ± 0.05 28
CO2 33.0 ± 0.7 31
N2 34.8 ± 0.2 31
protons 100 keV methane-TE 31.0 ± 1.5 31
propane-TE 28.2 ± 0.3 35
100 keV
70 MeV
methane
methane
30.5 ± 1.0
27.9*
31
40
100 MeV N2 36.5 ± 1.5 31
>1 MeV air (humid) 34.8 ± 0.7 2,41
>1 MeV air (dry) 34.2 ± 0.1 42
 particles 5.3 MeV methane 29.1 ± 1.0 31
methane-TE 31.1 ± 0.3 31
N2 36.39 ± 0.23 31
He2+ 3 MeV/amu air 35.0 + 1.3 39
3He** 10.3 MeV/amu air 34.5 ± 1.0 43
C6+ 2.5 – 4.5
MeV/amu
propane-TE 24.4* 39
C6+ 3 MeV/amu air 32.7 ± 1.3 39
C** 6.7 MeV/amu air 36.2 ± 1.0 43
C** 7.6 MeV/amu air 34.2 ± 1.0 38
C** 129 MeV/amu air 33.7* 43
C6+ 250 MeV/amu N2 36.6 ± 0.7 44
C6+ 250 MeV/amu N2 36.4 ± 0.6 45
N7+ 3 MeV/amu air 33.4 ± 1.3 39
Ne10+ 375 MeV/amu N2 35.4 ± 0.8 45
Ar18+ 479 MeV/amu N2 34.7 ± 0.5 45
** Errors not given in the original paper/
pogreška nije navedena u originalnom radu
** Ion charge not specified in original paper/
naboj iona nije naveden u originalnom radu
For carbon ions as incident particles a few sets of experi-
mental data on W exist46–51 (Fig. 5) covering a region of rela-
tively low ion energies. The data show similar energy de-
pendence in all gases. The constant high-energy W value
has not been reached even at 5 MeV/amu in methane-ba-
sed TE gas. The available w values in propane-based TE gas
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(24.4 eV39) and in N2 (36.6,44 36.4 eV45) are also signifi-
cantly lower than the W in the same gas at the highest ener-
gy shown in Fig. 5. It can be noticed that for the presented
gases the W is the lowest in propane, and the highest in N2.
Also, different sets of W for carbon ions in methane-based
TE gases do not agree in the common energy range (100 –
400 keV/amu). When different ions are compared in the
same gas, the W value at a particular energy in a given gas is
generally higher for the heavier ion28,35 and all data show si-
milar energy dependence of W.
From the presented data it can be concluded that there is a
need for new W value measurements for heavy-ion inter-
actions with tissue and tissue-like materials for ion energies
higher than ~10 keV/amu, and especially in energy ranges
of several hundreds of MeV/amu that are of interest in the-
rapy. Having in mind the recent study of the harmful effect
of secondary low-energy particles in the region beyond the
Bragg peak, it would be of interest also to study W for vari-
ous ions in the low-energy region where significant energy
dependence is expected.
Heavy-ion therapy
Radiotherapy by using protons and heavy ions was pro-
posed as early as in 1946,52 when the potential benefit of
heavy ions was first brought to attention. Since then the
physical and biological characteristics of various heavy par-
ticles have been studied. The heavy-ion therapy was first
applied 1977 at the University of California Lawrence Ber-
keley Laboratory (LBL). Mostly neon ions were used.19 In
1992 the LBL facility was entirely discontinued due mainly
to financial difficulty. Currently, there are three heavy-ion
therapy facilities: HIMAC (Heavy Ion Medical Accelerator
in Chiba, Japan), HIBMC (Hyogo Ion Beam Medical Center,
Japan) and GSI (Gesellschaft für Schwerionenforschung,
Darmstadt, Germany).53 The HIMAC construction and in-
stallation of all facilities were completed in 1993 and it was
the world’s first heavy ion accelerator complex dedicated to
medical use in a hospital environment. Carbon ions were
selected for clinical studies based on their high RBE in the
Bragg peak region (3.0).19 There are several new facilities
under construction, e.g. in Heidelberg, Germany54 (it will
be the first clinical irradiation facility for heavy ions in Eu-
rope with the capacity of 1000 patients per year), and Pave,
Italy,7 and some more are in the planning stage (in France,
Sweden, Austria).7
Over 2400 patients have been treated in the heavy-ion faci-
lities since 1994 – more than 2100 patients were treated
between 1994 and 2005 at HIMAC,55 about 250 at GSI
between 1997 and 2004,7,56 and more than 50 at HIBMC in
the period 2001 – 2004.7 They all have shown impressive
results of local control rates for some types of malignant, ot-
herwise untreatable cases. The major obstacles of heavy-
-ion therapy facilities, despite their potential, are the costs
for the construction, maintenance and treatment. As a mea-
sure, the construction cost of HIMAC was about 400 M$,
while the photon facility (x-ray and -ray) may be con-
structed for about 20 M$. The cost and complexity of the
exploitation of heavy-ion beams require often an internati-
onal collaboration.
Before treating a patient, radiation oncologists have to iden-
tify the precise location of the tumor by imaging. This is of-
ten done using another physics-based technique – positron
emission tomography (PET).7 The energy of the heavy-ion
beam – which is generally between about 300 and 400
MeV/amu –is then adjusted to match the tumor depth. Mo-
reover, by combining ions with different energies in a single
beam, the Bragg peak can be modulated into a plateau that
dumps a high dose of radiation throughout the depth of the
tumor (SOBP, Fig. 3). A recent attempt at HIMAC in Chiba
was made to synchronize the beam irradiation timing with
the body movement such as the patient breathing so that it
increases the precision of irradiation making the pin-point
shooting possible.
Increased biological effectiveness (RBE) of heavy charged
particle beams (e. g. carbon ions) in the tumor in compari-
son to the lower RBE in the surrounding healthy tissue re-
presents one of the major rationales for their application in
tumor therapy. Although the production of x-rays is more
economical and much easier in comparison with the pro-
duction of heavy charged-particle beams, the available cli-
nical experience with fast neutrons and protons justifies the
heavy-ion therapy programs by four sets of arguments:
1. the radiobiology and clinical data indicate that, for the
treatment of some tumor types and/or sites, high-LET radia-
tions could bring benefit as compared to low-LET radiations
2. the attainability of high physical selectivity
3. the encouraging clinical results, although obtained on li-
mited and selected groups of patients
4. less side effects than other radiations and chemothera-
pies.
To explain some of these arguments, summaries of clinical
results at Japanese facilities are shown in Tables 2 and 3.
The comparison of 1–, 2– and 5–year survival rates for
heavy-ions and x-ray treatments (Table 2) clearly shows the
advantage of heavy-ion treatment as could be expected
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F i g. 5 – Energy dependence of the W value (the mean energy
required to form an ion pair) for carbon ions in several gases of inte-
rest for radiation therapy
S l i k a 5 – Energijska ovisnost srednje energije potrebne za stva-
ranje ionskog para (W) za ugljikove ione u plinovima od interesa za
radioterapiju
from the arguments above, although limited data are avai-
lable for comparison.
The results of local control rates obtained by heavy-ion the-
rapy in comparison with a conventional treatment (x-ray
plus chemotherapy) are shown in Table 3. The local control
rate means the percentage of the original cancer treated by
any of these procedures and found to be well under con-
trol, although the patient might have died from the cancer
at a different site. For most cases, again, it can be seen that
heavy-ion treatment shows better results over conventional
treatment, particularly impressive for treatments of salivary
gland, nasopharynx and prostate malignancies. The LBL ex-
perience with heavy-ion therapy showed similar benefits
for tumors of salivary glands and prostate, while for other lo-
calizations the results were poor.2 Clinical experience at
GSI since 199756 shows much better local control of pa-
tients having Chordomas when treated by carbon ions (lo-
cal control after 3 years 81 %) than by photons (55 %). Also
successfully were treated Chondrosarcomas (3–year local
control rate 100 %).
The growing number of cancer patients treated by heavy-
ion beams and the successful patient survival rates and local
tumor controls have recently drawn attention to studies of
potential late radiation effects in surviving patients. A radi-
otherapy treatment can be considered as successful when
the balance between cure and unwanted late effects is fo-
und.57 Potential late effects are associated with irradiated
normal tissue. As mentioned earlier, at higher doses both
the probability of tumor control and that of normal tissue
complications increase. The dose-depth distribution, i. e.
the Bragg peak, and higher RBE of carbon ions diminish the
chance of normal tissue irradiation compared to irradiation
by x-rays. However, if the normal tissue is irradiated, the
high LET of carbon ions increases the risk of induced tumors
and other enhanced late effects. Estimation of late effects
has a further handicap in a relatively small number of trea-
ted patients and shorter follow-up time.57
Since more new heavy-ion facilities become available for
clinical trials in the next years, more data for better compa-
rison and illustration should become available making a
better judgment possible. In addition, as discussed above,
further deepening of our understanding of radiation phy-
sics, chemistry and biology of heavy-ion interactions is ur-
gently required in order to enable clinical personnel to
implement much better treatment plans and designs.
Concluding remarks
Heavy ions applied in radiation therapy combine the ad-
vantages of a high physical selectivity and high LET for some
types of tumor. The higher RBE at the level of the Bragg
peak or the spread-out Bragg peak and lower OER values
further improve the advantage of the characteristic dose
distribution. Having these properties, heavy ions are consi-
dered to be more effective than other types of radiation in
treatment of hypoxic tumors, deep-seated tumors, or slow-
ly growing tumors, generally of tumors that are resistant to
low-LET radiation.
Understanding biological consequences of energy loss by
charged particles, such as high-energy therapeutic ion be-
ams requires access to a wide range of atomic and molecu-
lar data. The primary means of energy deposition of fast
charged particles is ionization of a medium with the spatial
pattern determined by subsequent energy transport by se-
condary electrons. The applications of high-LET radiations
to radiation therapy and radiation research suffer because
of the large gaps in our knowledge of atomic and molecular
data for this type of radiation that can be related to the pau-
city of well characterized heavy-ion sources available for re-
search. Very little is known about physical and chemical
reactions occurring inside the Bragg peak after the incident
high-energy heavy ion had deposited most of its energy in a
small volume, particularly, the role of radicals and ions, in
addition to the direct damage of DNA by densely ionizing
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T a b l e 2 – Comparison of survival rates after x-ray and he-
avy-ion treatments 1 year, 2 years, and 5 years after treatment
T a b l i c a 2 – Usporedba postotka preÞivjelih pacijenata pod-
vrgnutih terapiji x-zrakama i teškim ionima godinu dana, 2 godine i
5 godina nakon tretmana
Survival rates (%)
Udio preÞivjelih (%)
Radiation
Zraèenje 1 yr 2 yrs 5 yrs
Head-neck
Glava i vrat
x-ray 90 75 58
Heavy-ion 90 79 69
Lung
Pluæa
x-ray 78 55 22
Heavy-ion 95 82 42
Bones
Kosti
x-ray 15 - -
Heavy-ion 86 60 49
T a b l e 3 – Local control rates of tumors by irradiation with
heavy-ion and by conventional treatment (x-rays + chemotherapy)
T a b l i c a 3 – Postotak tumora pod lokalnom kontrolom nakon
radioterapije teškim ionima i konvencionalne terapije (x-zrake i ke-
moterapija)
Heavy-ion (%)
Teški ioni (%)
Conventional
treatment (%)
Konvencionalna
terapija (%)
Salivary gland
Ýlijezda slinovnica
80 28
Nasopharynx
Nosni dio Þdrijela
63 21
Sarcoma
Sarkom
56 28
Prostate
Prostata
100 60 – 70
Lung
Pluæa
40 22 – 40
Brain
Mozak
44 18
radiations is not well understood. The role of radicals and
different ions formed there and their interaction with DNA
should be carefully investigated. The need for new experi-
mental data on the basic physical quantity of dosimetry, the
mean energy required to form an ion pair (W) in tissue and
tissue-equivalent materials, for high-energy heavy ions re-
quired in radiotherapy is especially emphasized.
Future advances in radiotherapy will depend considerably
on a better understanding of the underlying mechanism of
radiation actions on human cells. Contemporary biophysi-
cal models of radiation action now agree that biological ef-
fects are strongly influenced by radiation track structures on
a scale of cellular dimensions down to nanometers or even
smaller. However, the successful application of radiothe-
rapy by heavy ions is going on, in spite of missing funda-
mental knowledge of detailed chemical and biological pro-
cesses in tissue irradiated by high-LET radiation. The new
heavy-ion facilities, both for basic research and clinical ap-
plications, will certainly result in a better understanding of
various processes induced by heavy ions in both cancerous
and healthy tissue.
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List of symbols
Popis simbola
LET – Linear Energy Transfer, keV/m
– linearni prijenos energije, keV/m
E – energy, eV or keV or MeV, for heavy ions: MeV/amu
– energija, eV ili keV ili MeV, za teške ione: Mev/amu
W – mean energy required to form an ion pair, eV
– srednja energija stvaranja ionskog para, eV
w – differential mean energy for an ion pair, eV
– diferencijalna srednja energija stvaranja ionskog para, eV
N – total number of electrons produced after complete
dissipation of the initial energy of a charged particle
– ukupni broj elektrona nastalih nakon potpunog gubitka
poèetne energije ionizirajuæe èestice
dE – differential mean energy loss, eV
– diferencijal gubitka energije, eV
dl – differential path length, m
– diferencijal puta, m
dN – differential number of ion pairs
– diferencijal broja elektrona
dx – differential thickness, m
– diferencijal debljine, m
D – dose, Gy
– doza, Gy
Abbreviations
Popis kratica
RBE – Relative Biological Effectiveness
– relativna biološka uèinkovitost
OER – Oxygen Enhancement Ratio
– omjer pojaèanja zbog prisustva kisika
SOBP – spread-out Bragg peak
– prošireni Braggov vrh
TE – tissue-equivalent
– tkivu ekvivalentan
amu – atomic mass unit
– atomska jedinica mase
HIMAC – Heavy Ion Medical Accelerator in Chiba
HIBMC – Hyogo Ion Beam Medical Center
GSI – Gesellschaft für Schwerionenforschung
PET – positron emission tomography
– pozitronska emisijska tomografija
TCP – tumor control probability
– vjerojatnost kontrole tumora
NTCP – normal tissue complication probability
– vjerojatnost komplikacija zdravog tkiva
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SAÝETAK
Fizika i kemija zraèenja u terapiji raka teškim ionima
I. Krajcar Broniæa i M. Kimurab
Teški ioni, kao što su ioni ugljika i kisika, ubrajaju se u zraèenje visokog linearnog prijenosa energi-
je (LET) i prolaskom kroz tkivo stvaraju karakteristiènu raspodjelu deponirane energije (doze) po
dubini prodiranja koja se bitno razlikuje od raspodjele doze koju stvara zraèenje niskog LET-a
(-zrake, x-zrake, elektroni). Teški ioni gube manji dio energije pri ulasku u ozraèeni biološki sus-
tav, a zatim gube gotovo svu energiju u vrlo malom volumenu. Podruèje maksimalne deponirane
energije naziva se Braggov vrh, koji ovisi o vrsti i energiji primijenjenog iona. Koristeæi svojstvo
Braggovog vrha, moguæe je ozraèiti samo podruèje tumora na nekoj dubini unutar tkiva, a isto-
dobno izbjeæi (štetno i nepotrebno) ozraèenje okolnog zdravog tkiva. Postojanje Braggovog vrha
nije jedina prednost teških iona pred zraèenjem niskog LET-a – teški ioni naime pokazuju manji
omjer pojaèanja zbog prisustva kisika (OER) i veæu relativnu biološku uèinkovitost (RBE). Smatra
se da je središnje podruèje dubinskog tumora slabo prokrvljeno te da je kolièina kisika u tom pod-
ruèju stoga smanjena. IstraÞivanja su pokazala (slika 1) da je biološki uèinak zraèenja niskog LET-a
znatno veæi (OER = 3) u uvjetima dobre oksidacije tkiva, dok je razlika biološkog uèinka zraèenja
visokog LET-a znatno manja (OER = 1,6, slika 1), pa su dakle teški ioni znatno uèinkovitiji u uniš-
tavanju dubinskih slabo oksidiranih tumora. RBE je definiran kao omjer doze referentnog zra-
èenja (x-zrake energije 200 keV) i doze danog zraèenja potrebne za postizanje istog biološkog
uèinka. Viša vrijednost RBE znaèi da se manjom dozom postiÞe isti biološki uèinak, te se tako po-
stiÞe i bolji omjer korisnosti i rizika radioterapije. RBE ovisi o LET (slika 2), a za razlièite ione koji se
primjenjuju u radioterapiji postiÞe maksimum na razlièitim vrijednostima LET-a. Slika 3 prikazuje
raspodjelu deponirane energije po dubini u tkivu za protone i ugljikove ione kao primjer zraèenja
visokog LET-a. Karakteristièan Braggov vrh postiÞe se na veæim dubinama primjenom viših ionskih
energija, a kombinacijom snopova iona bliskih, ali razlièitih energija moÞe se postiæi prošireni
Braggov vrh (SOBP), te se tako moÞe jednoliko ozraèiti cjelokupni volumen dubinskog tumora. Za
usporedbu prikazana je i raspodjela doze po dubini za fotone, koja dosiÞe maksimum na maloj
dubini ispod površine koÞe (zbog stvaranja sekundarnih elektrona), nakon èega slijedi gotovo
eksponencijalni pad doze s dubinom. Omjer doze primljene u podruèju tumora i doze izvan tu-
mora znatno je manji nego u sluèaju protona ili ugljikovih iona.
Na osnovi tih èinjenica moÞe se zakljuèiti da je podruèje Braggovog vrha podruèje u kojem je uèi-
nak terapije tumora teškim ionima najveæi. Za bolje planiranje tretmana i postizanje boljih kliniè-
kih rezultata potrebno je stoga detaljno poznavanje fizikalnih i kemijskih procesa koji se odvijaju
u tkivu nakon ozraèenosti teškim ionima energije oko 300 MeV/amu. Nakon ulaska u tkivo takvi
ioni gube kinetièku energiju u elastiènim sudarima s molekulama. Kad energija padne na nekoli-
ko stotina keV, prevladavaju procesi elektronskog pobuðenja i ionizacije uzrokujuæi nagli gubitak
velike kolièine energije, i to je podruèje Braggovog vrha. Kad je energija iona pala u podruèje keV
ili èak eV, a to je podruèje pri kraju Braggovog vrha, dogaðaju se i drugi procesi, kao prijenos na-
boja, rotacijska i vibracijska pobuðenja, uhvat elektrona, razna raspršenja. Molekularni ioni nasta-
li u tim procesima, kao i neki drugi produkti reakcija, vrlo su èesto nestabilni i brzo se raspadaju.
Fragmentacijom nastaju razlièiti radikali i ioni koji mogu imati dovoljno energije da prijeðu zna-
èajnu udaljenost od mjesta svog nastanka i na udaljenom mjestu reagiraju s biomolekulama i iza-
zivaju ošteæenja. Meðutim, ne zna se mnogo o detaljima svih ovih nabrojanih procesa koji èine
ukupnost djelovanja zraèenja visokog LET-a u podruèju Braggovog vrha, ali i neposredno iza nje-
ga. Posebno je potrebno istraÞiti ulogu radikala i iona koji su nastali meðudjelovanjem zraèenja i
vode, koja èini znaèajnu komponentu svakog biološkog sustava, te njihovo djelovanje na DNA.
Osnovni princip radioterapije je pronaæi naèin da se predviðena doza preda podruèju tkiva u
kojem se nalazi tumor, dok je dozu u okolnom tkivu potrebno što više smanjiti. Slika 4 prikazuje
vjerojatnosti kontrole tumora i komplikacija u zdravom tkivu u ovisnosti o dozi, te podruèje doza
u kojem se postiÞe najbolji terapijski uèinak bez komplikacija zdravog tkiva (terapijski prozor). Ka-
ko bi se ostvario najbolji moguæi uèinak radioterapije, potrebno je dakle poznavati i mjeriti dozu
predanu tkivu, što je zadatak dozimetrije. Mjerenja se uglavnom zasnivanju na mjerenju elektro-
na koji nastaju meðudjelovanjem svih vrsta zraèenja i tvari. Nepouzdanost mjerenih doza ovisi o
nepouzdanosti osnovnih fizièkih velièina, kao što su moæ zaustavljanja i ukupni broj stvorenih
elektrona. Broj elektrona najèešæe se izraÞava pomoæu velièine W, srednje energije potrebne za
stvaranje ionskog para, koja se definira kao prosjeèna energija koju je upadna ionizirajuæa èestica
energije E utrošila na stvaranje jednog para elektron – pozitivni ion nakon što je èestica potpuno
zaustavljena. W ovisi o vrsti i energiji zraèenja te o ozraèenoj tvari. Za èestice vrlo visokih energija,
koje samo dio energije ostave u tkivu, koristi se diferencijalna srednja energija stvaranja ionskog
para, w. Za dovoljno visoke energije vrijedi aproksimacija w = W. Dostupni podaci o W ili w u li-
teraturi su naÞalost nepotpuni i nesustavni, što pogotovo vrijedi za teške ione. Veæina podataka
odnosi se na relativno niske energije, kao što pokazuje primjer W za ugljikove ione u raznim pli-
novima (slika 5). Vrijednosti w za ione viših energija prikazani su u tablici 1, a za usporedbu dane
su i vrijednosti W za druge vrste ionizirajuæeg zraèenja. Za potrebe radioterapije potrebna su nova
mjerenja W ili w za ione visokih energija u tkivu ili tkivu ekvivalentnim smjesama.
Medicinska primjena ugljikovih iona u radioterapiji tumora poèela je u Japanu i Njemaèkoj 1994.
godine i od tada je više od 2400 pacijenata podvrgnuto radioterapiji teškim ionima. Prvi klinièki
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rezultati pokazuju veliku uspješnost u terapiji dubinski smještenih tumora, te je tako opravdana
visoka cijena gradnje takvih terapijskih centara. Tablica 2 pokazuje usporedbu postotka preÞiv-
jelih pacijenata podvrgnutih terapiji x-zrakama i teškim ionima godinu dana, dvije godine i pet
godina nakon tretmana, a tablica 3 prikazuje postotak tumora pod kontrolom nakon radioterapije
teškim ionima i konvencionalne terapije (x-zrake i kemoterapija). U veæini sluèajeva bolji rezultati
postignuti su terapijom teškim ionima. Radioterapija teškim ionima, uglavnom ugljikovim, nastav-
lja se i u novim terapijskim centrima unatoè visokom ulaganju i nedostatnom poznavanju osnov-
nih kemijskih i bioloških procesa u tkivu ozraèenom zraèenjem visokog LET-a. Nova saznanja iz
podruèja radijacijske fizike, kemije i biologije pomoæi æe u daljnjem poboljšanju planiranja tera-
pije teškim ionima te time i u postizanju još boljih klinièkih rezultata.
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